삼성바이오로직스중립
The recent decision by the Samsung Biologics labor union to withdraw from the Samsung Group Super-Enterprise Union suggests a shift toward independent labor relations. While this may introduce short-term uncertainty regarding labor-management relations, the company’s strategic pivot toward a platform business model—aimed at securing long-term early lock-in of global clients—remains the primary driver of its fundamental value. Investors should monitor whether this organizational change impacts operational stability or if the company maintains its growth momentum through its new technology export initiatives.
셀트리온중립
Celltrion is currently navigating a transitional phase characterized by both strategic portfolio optimization and long-term R&D investment. The decision to voluntarily withdraw the Phase 3 clinical trial for the Keytruda biosimilar (CT-P51) suggests a strategic pivot, likely to refine development timelines or address competitive landscape shifts in the oncology market. Conversely, the company’s focus on AI-driven drug discovery and the expansion of its next-generation pipeline at BIO USA underscore a commitment to long-term innovation beyond its core biosimilar business. While the withdrawal may trigger short-term market sensitivity, the company’s sustained investment in R&D infrastructure and its solid performance in the European market remain key pillars for future valuation.
유한양행중립
As Yuhan Corporation approaches its centennial anniversary, the company is strategically balancing its historical legacy—rooted in the ‘Founder’s Spirit’ (Yu Il-han)—with the necessity for modern organizational evolution. While the recent unveiling of the ‘Willow House’ serves to reinforce corporate identity and stakeholder trust, the core investment thesis remains tethered to the company’s ability to navigate a rapidly shifting pharmaceutical landscape. For the next century, Yuhan must transition from its traditional foundation toward enhanced market responsiveness and agile leadership to maintain its competitive edge in R&D and global expansion. The focus on internal communication and leadership succession will be critical in translating this century-long heritage into sustainable shareholder value.
알테오젠호재
Alteogen is currently transitioning from a pure R&D-focused biotech to a sustainable cash-flow generator through its proprietary SC (Subcutaneous) formulation technology. The recent resolution of patent disputes and the favorable ruling regarding the intellectual property (IP) landscape significantly mitigate the legal risks that previously weighed on the company’s valuation.
Furthermore, the company’s strategic shift toward royalty-based revenue streams marks a critical inflection point, validating the commercial viability of its platform. With management signaling a focus on modality expansion and potential KOSPI transfer listing, Alteogen is well-positioned to improve its institutional investor base and long-term capital structure. The focus now shifts to the execution of global licensing deals and the realization of recurring high-margin royalties.
HLB악재
The recent regulatory setback for HLB’s Rivoceranib, intended for the treatment of hepatocellular carcinoma, represents a significant hurdle in the company’s path to commercialization. The FDA’s decision to withhold approval, primarily citing issues related to the Complete Response Letter (CRL) and concerns regarding the manufacturing facility of its partner, Hengrui Pharma, introduces substantial uncertainty. While the company has indicated that some inspection findings (VAI status) have been addressed, the repeated delays underscore the complexities of cross-border regulatory compliance and quality control. Investors should remain cautious as the timeline for resubmission and subsequent approval remains fluid, posing a risk to the company’s near-term valuation and market sentiment.